CLINICAL TRIALS PROFILE FOR INTRALIPID 10%

All Clinical Trials for Intralipid 10%

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00005889 ↗	Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion	Unknown status	Baylor College of Medicine	N/A	1999-10-01	RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels.
NCT00005889 ↗	Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion	Unknown status	National Center for Research Resources (NCRR)	N/A	1999-10-01	RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels.
NCT00048646 ↗	Progesterone Treatment of Blunt Traumatic Brain Injury	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 1/Phase 2	2002-05-01	The purpose of this study is to determine if progesterone treatment safely reduces brain swelling and damage after injury.
NCT00048646 ↗	Progesterone Treatment of Blunt Traumatic Brain Injury	Completed	David Wright	Phase 1/Phase 2	2002-05-01	The purpose of this study is to determine if progesterone treatment safely reduces brain swelling and damage after injury.
NCT00074477 ↗	Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 2	2003-10-01	The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate injection compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.
NCT00088647 ↗	Study Evaluating MST-997 in Advanced Malignant Solid Tumors	Terminated	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 1	1969-12-31	The primary objective of this clinical research study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of intravenous (IV) MST-997 formulated in Intralipid 20% administered on a weekly schedule to subjects with advanced malignant solid tumors.
NCT00101634 ↗	Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2004-12-01	The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.

Clinical Trial Conditions for Intralipid 10%

Condition Name

Condition Name for Intralipid 10%
Intervention	Trials
Parenteral Nutrition	6
Obesity	6
Cholestasis	5
Hypertension	5

Condition MeSH

Condition MeSH for Intralipid 10%
Intervention	Trials
Insulin Resistance	10
Cholestasis	8
Liver Diseases	5
Infertility	5

Clinical Trial Locations for Intralipid 10%

Trials by Country

Trials by Country for Intralipid 10%
Location	Trials
United States	76
Canada	14
Egypt	9
France	4
Netherlands	3

Trials by US State

Trials by US State for Intralipid 10%
Location	Trials
New York	7
Texas	6
Massachusetts	5
Tennessee	5
Ohio	5

Clinical Trial Progress for Intralipid 10%

Clinical Trial Phase

Clinical Trial Phase for Intralipid 10%
Clinical Trial Phase	Trials
Phase 4	27
Phase 3	11
Phase 2/Phase 3	7

Clinical Trial Status

Clinical Trial Status for Intralipid 10%
Clinical Trial Phase	Trials
Completed	45
Terminated	9
Recruiting	8

Clinical Trial Sponsors for Intralipid 10%

Sponsor Name

Sponsor Name for Intralipid 10%
Sponsor	Trials
Fresenius Kabi	5
Emory University	5
Baxter Healthcare Corporation	4

Sponsor Type

Sponsor Type for Intralipid 10%
Sponsor	Trials
Other	94
Industry	21
NIH	3